Table 2.
Annual total costs and patient out-of-pocket costs ($) for second-generation antipsychotics per user for off-label and on-label users, 2006–2012
| Year | Off-label | On-label | Second-generation antipsychotics with patents expiring | ||||
|---|---|---|---|---|---|---|---|
| OOP cost | Total cost | Ratio | OOP cost | Total cost | Ratio | ||
| 2006 | 72 | 2,305 | .031 | 54.28 | 3,852 | .014 | |
| 2007 | 144 | 2,378 | .060 | 106.34 | 4,017 | .026 | |
| 2008 | 148 | 2,612 | .056 | 109.99 | 4,364 | .025 | Risperdal |
| 2009 | 133 | 2,500 | .053 | 105.52 | 4,279 | .025 | |
| 2010 | 137 | 2,512 | .054 | 104.45 | 4,525 | .023 | |
| 2011 | 116 | 2,800 | .042 | 87.28 | 4,981 | .018 | Zyprexa |
| 2012 | 76 | 2,163 | .035 | 72.37 | 3,962 | .018 | Seroquel, Invega, Geodon |
| Average growth rate (%) | 7.81% | −.34% | 10.12% | 1.06% | |||
Notes: OOP=out-of-pocket